ACA
SPRY icon

American Capital Advisory’s ARS Pharmaceuticals SPRY Stock Holding History

American Capital Advisory’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,570
Closed -$136K – 1138
2025
Q3 		$136K Buy
13,570
+157
+1% +$2.25K 0.06% 118
2025
Q2 		$234K Buy
+13,413
New +$194K 0.12% 90

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Capital Advisory's SPRY Position: Q4 2025 in Review

American Capital Advisory sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 13,570 shares — an estimated $136K sold.

American Capital Advisory first reported a position in SPRY in Q2 2025 and held it in 2 quarters. The position peaked at $234K in Q2 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • American Capital Advisory reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • American Capital Advisory sold 13,570 ARS Pharmaceuticals shares in Q4 2025, an estimated $136K.
  • American Capital Advisory first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • American Capital Advisory's ARS Pharmaceuticals position peaked at $234K in Q2 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on American Capital Advisory's 13F filing for Q4 2025, filed 30 Jan 2026.